Multiple myeloma (MM) is characterized by the expansion of malignant plasma cells in the bone marrow (BM). Most MMs display aberrant Wnt/β-catenin signaling, which drives proliferation; however, they lack oncogenic Wnt-pathway mutations, suggesting activation by autocrine Wnt ligands and/or paracrine Wnts from the BM microenvironment.
INTRODUCTION
Multiple myeloma (MM) is an in most patients incurable hematologic neoplasm characterized by the accumulation of malignant plasma cells in the bone marrow (BM). Notwithstanding the diversity of underlying structural and numerical genomic abnormalities [1] [2] [3] , virtually all
MMs are highly dependent on a protective BM microenvironment for growth and survival.
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The membrane-bound heparan sulfate proteoglycan (HSPG) syndecan-1 has been identified as a critical player in this complex reciprocal interaction between MM cells and their BM 'niche'. 5, 6 Consequently, targeting syndecan-1 could be employed as strategy to disconnect MM cells from their BM 'niche'.
Expression of the HSPG syndecan-1 is characteristic of plasma cells and their malignant
MM counterparts 7 and plays a crucial role in MM cell growth and survival. 6, 8, 9 HSPGs are a class of extracellular matrix or cell-membrane-bound glycoproteins designed to specifically bind and regulate the bioactivity of soluble protein ligands 10, 11 and play an essential role in the spatial control of extracellular signals regulating cell growth, survival, and differentiation, including tumorigenesis. [11] [12] [13] They consist of a protein core with covalently attached polysaccharide heparan sulfate (HS) chains. These HS chains undergo a series of processing reactions involving N-deacetylation/N-sulfation, epimerization,
and O-sulfation. 10, 11 This endows HS chains with highly modified domains, which provide specific docking sites for a large number of bioactive molecules, such as growth factors and cytokines, and serve a variety of functions ranging from immobilization and concentration to distinct modulation of signaling. [13] [14] [15] On MM cells, syndecan-1 is the principal, if not sole, HSPG. 8, 9 The HS-chains decorating syndecan-1, mediate interaction between the tumor cells and growth factors from the BM microenvironment, 6 including hepatocyte growth factor (HGF), epidermal growth factor (EGF)-family members, and APRIL. 5, 8, 16 In addition, syndecan-1 may also regulate Wnt signaling, 17 which has been implicated in driving MM proliferation and is associated with disease progression, dissemination, and drug resistance. [18] [19] [20] [21] [22] Wnts are lipid-modified glycoproteins that function as typical niche factors since they are relatively unstable and insoluble due to their hydrophobic nature, which constrains long-range signalling. 23 Binding of a Wnt ligand to its receptor roles in the pathogenesis of MM. [26] [27] [28] The turnover of the Wnt receptor Fzd is critically regulated by LGR-family receptors and their cognate R-spondin ligands. R-spondin/LGR binding alleviates the inhibitory effect of two homologous membrane-bound E3 ubiquitinligases, ZNRF3 and RNF43, which promote Fzd internalization, thereby controlling the amplitude of Wnt signaling. [29] [30] [31] [32] Aberrant Wnt signaling in cancer typically results from mutations in APC, β-catenin (CTNNB1), or AXIN that drive constitutive, ligand-independent pathway activation. 32 However, MMs displaying active Wnt signaling do not harbor these classic mutations.
Instead oncogenic Wnt pathway activity in MM involves autocrine and/or paracrine Wnt ligands, 19, 21, 32, 33 and is potentiated by aberrant expression and turnover of Wnt (co-)receptors and transcriptional activators, as well as by loss of negative Wnt pathway regulators. These activating events include aberrant expression of the R-spondin receptor LGR4, 34 and of the transcriptional co-activator BCL9, 35, 36 epigenetic silencing of the feed-back inhibitors sFRPs and DKK1, 21, 33 and mutational inactivation of CYLD, a deubiquinating enzyme that negatively regulates Wnt. 37 Given the ligand-dependence of Wnt pathway activation in MM, targeting of Wnt (co)receptors, disconnecting the MM cells from their growth-promoting microenvironment, is a potentially promising therapeutic strategy for MM. This prompted us to explore the specific contribution of syndecan-1 HS to Wnt-signaling activation in MM.
MATERIALS AND METHODS

Cell culture and treatment
The human multiple myeloma cell lines (HMCLs) LME-1, LP1, OPM-2, RPMI 8226 (RPMI), XG-1, RIES and XG-3 were cultured in IMDM medium (Invitrogen Life Technologies) containing 10% FBS (Invitrogen Life Technologies), 100 units/ml penicillin (Sigma Aldrich), 100 µg/ml streptomycin (Sigma Aldrich). For XG-1, XG-3, LME-1 and RIES, medium was supplemented with 500 pg/mL IL-6 (Prospec). Primary MM cell samples were derived from patients diagnosed at the Academic Medical Center, Amsterdam, the Netherlands.
This study was conducted and approved by the AMC Medical Committee on Human Experimentation. Informed consent was obtained in accordance with the Declaration of Helsinki. For signal transduction experiments, recombinant hWnt3a (R&D systems) was used at 100ng/mL, recombinant hR-spondin1 at 50ng/mL (R&D systems) unless otherwise stated. Wnt inhibitors used were IWP-2 (2.5uM, Stemgent) and LGK974 (2.5uM, StemRD).
For heparitinase treatment, 300,000 MM cells were treated with 5 mU heparitinase (Amsbio) for 60 min at 37°C.
Cloning, transfection and transduction
The dnTCF4 construct were obtained from addgene (52961); S33Y β-catenin was generated by inserting S33Y β-catenin into the HPAI site of pHIV-H2BmRFP (Addgene 18982). pTRIPZ-shEXT1 was customly constructed. In short, a 97-mer template was inserted in the XhoI/EcoRI site of the pTRIPZ vector (Thermo Scientific, Waltham, MA). 
In vitro cell growth and apoptosis
In vitro cell growth and apoptosis were performed as described before. 6 For full detail, see Supplemental methods.
Confocal microscopy
The reduction in heparan sulfate expression after EXT-1 knock-out was evaluated by confocal microscopy. For full detail, see Supplemental methods.
Cell cycle analysis
Cells were incubated for 1h with 20µM BrdU (Sigma Aldrich) and subsequently fixed in ice- 110
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For cell cycle analysis of Wnt responsive cells (Fig. S4 ), see Supplemental methods.
Immunoblotting
Immunoblotting were perform as describe before. 34 For full detail, see Supplemental methods.
Flow cytometry
Cell staining was analyzed by flow cytometry. For full detail, see Supplemental methods.
RESULTS
Human myeloma cell lines display constitutive Wnt-signaling
Previous studies have shown that activation of the canonical Wnt pathway is common in advanced primary MMs and in human myeloma cell lines (HMCLs). [19] [20] [21] [22] This aberrant Wnt signaling activity is driven by autocrine and/or paracrine Wnt ligands and promotes MM proliferation. 19, 22 To confirm and extend these findings, we expressed a dominant negative TCF4 (dnTCF4) from a lentiviral vector containing a mCherry marker in HMCLs and measured the percentage of transduced cells over time. dnTCF4 transduced myeloma cells were rapidly outcompeted, whereas the percentage of control vector transduced cells was stable ( Fig.1A and S1A), confirming that growth of these HMCLs indeed depends on Wnt signaling.
To explore the possible involvement of autocrine Wnt ligands, we tested the effect of the Wnt secretion inhibitors IWP-2 and LGK974 on myeloma growth. These small molecules inhibit the activity of Porcupine, a membrane-bound acyltransferase that is essential for the secretion of Wnt proteins. 40, 41 We found that both inhibitors significantly inhibit the growth of LP1 and LME1 (Fig.1B ) and that they indeed inhibit autocrine Wnt signaling (Fig.S1B) . Despite the significant reduction in cell numbers, both inhibitors hardly affected cell viability (Fig.S1C) . Importantly, downstream activation of Wnt signaling by an active mutant β-catenin (S33Y β-catenin) overcame the growth inhibition by IWP2 and LGK974 (Fig.1C) . Taken together, these findings suggest that autocrine Wnt ligands are involved in Wnt pathway activation and cell growth in these HMCLs.
Deletion of heparan sulfate by EXT1 knock-out inhibits Wnt-signaling in HMCLs
HSPGs, including syndecan-1, have previously been implicated in the regulation of Wnt signaling, including Wnt-mediated tumorigenesis. 17 To explore the possible involvement of syndecan-1 HS in Wnt signaling in MM, we deleted the HS co-polymerase EXT1 in
HMCLs by CRISPR/Cas9-mediated knock-out (ko). This completely abolished cell-
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surface HS expression ( Fig. 2A) . To determine its effect on Wnt signaling, we measured the levels of nuclear and cytoplasmic β-catenin (Fig. 2B) , a key component of canonical Wnt signaling. In addition, TCF4-mediated Wnt-reporter activity was assessed in LP1 cells stably transduced with a fluorescent Wnt-reporter (TOP-GFP) and co-expressing a histone2B (H2B)/mCherry fusion protein as transduction-marker. As control, LP1 cells were transduced with FOP-GFP (Fig.2C ). As shown in Fig.2B , ko of EXT1 resulted in reduced β-catenin levels in both the nucleus and cytoplasm in three HMCLs studied. In contrast, phosphorylation of AKT and the MAP kinases ERK1/2, typically reflecting activation of growth factor signaling, was not affected in LME1 and LP1 (Fig.S2) . Furthermore, deletion of EXT1 resulted in a strong reduction in the percentage of TOP-GFP positive cells in LP1 (Fig.2D ). We also determined the effect of EXT1 ko on the expression of the Wnt target genes c-Myc and CCND1 (Cyclin D1). 20 As shown in 
Loss of HS inhibits MM cell growth by attenuating Wnt signaling
We have previously shown that knockdown (kd) of either EXT1 or syndecan-1 inhibits the growth of MM cells both in vitro and in vivo. 6 To confirm and extend these findings, we performed EXT1 kd in a panel of HMCLs (Fig.S3A) . Loss of HS resulted in a significant inhibition of cell growth in 4 out of 6 HMCLs ( Fig.3A and S3C ). Importantly, similar results were also obtained in primary MM cells. Since the poor ex vivo viability and growth of these cells prohibited viral transduction and subsequent selection to (inducible) silence EXT1 by shRNA, we employed heparitinase to remove HS. This resulted in a complete depletion of HS chains from the MM cell surface (Fig.3B ), resulting in a significant growth inhibition (Fig.3C ).
EXT1 kd only weakly affected cell viability in 2 of the HMCLs and did not induce apoptosis ( Fig.S3D and Fig.3D) ; however, it strongly decreased the percentage of cells in S-phase and slightly increased the percentage of cells in the sub-G1 phase, as determined by measuring DNA content and BrdU incorporation (Fig.3E) . Similarly, removal of HS in primary MM by heparitinase did not induce significant cell death (Fig.S3E ). These data indicate that loss of HS mainly affects MM growth by attenuating proliferation. Importantly, this growth inhibition could not be overcome by co-culture of MM cells with bone marrow stromal cells (BMSCs) (Fig.3F ).
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We next studied whether the growth inhibition by EXT1 kd was causally related to inhibition of Wnt signaling. To this end, we transduced LP1 and LME1 cells with the active mutant β-catenin (S33Y β-catenin), which activates Wnt signaling in the absence of ligand.
Interestingly, EXT1 kd did not cause growth inhibition in mutant β-catenin (S33Y β-catenin)
transduced cells while EXT1 kd in empty vector transduced cells resulted in a strong growth reduction (Fig.3G ). These findings suggest that the growth reduction by loss of HS is largely due to Wnt signaling inhibition. In view of our observation that EXT1 ko markedly reduces the expression of Wnt target c-Myc ( Figure 2E ), an established key player in B-cell 42 and MM 43 cell proliferation, we explored the possible role of c-Myc in the observed EXT1 kd mediated growth reduction. To this end, we overexpressed c-Myc in LP1 and LME1 cells (Fig.S3F ). In line with a previous study 43 this enhanced MM cell growth. EXT1 kd in empty vector transduced LP1 and LME1 cells resulted in a strong growth reduction (Fig.3H) . However, in c-Myc overexpressing cells, it did not significantly inhibit growth (Fig.3H ), suggesting that c-Myc downregulation plays an important role in the growth inhibition observed upon HS loss. To assess whether the HS chains decorating syndecan-1 play a role in Wnt pathway activation by exogenous/paracrine Wnts, we employed OPM2 and XG3, the HMCLs with a high Wnt3a response that is largely independent of co-stimulation via R-spondin/LGR4.
Loss of HS impairs Wnt pathway activation by paracrine Wnts
As shown in and primary MM cells. By contrast, ko of LGR4 (Fig.S9 ), the cognate R-spondin receptor on MM cells 34 , had no measurable effect on R-spondin cell surface binding (Fig.7C ).
All four R-spondins have a common thrombospondin protein (TSP) domain, which mediates glycosaminoglycan (GAG) binding. [59] [60] [61] To further study the functional role of R-spondin interaction with HS, we employed a mutant R-spondin (R-spondin-∆TSP), which lacks the TSP-domain and C-terminal basic amino-acid-rich domain. As a control, we used R-spondin which lacks the basic amino-acid-rich domain only (R-spondin-∆AA). Deletion of the TSP-domain strongly diminished the Wnt-signaling potentiating effect of R-spondin compared to the control R-spondin-∆AA. Whereas loss of cell surface HS significantly attenuated the potentiating effect of R-spondin-∆AA, it did not affect the (minor) potentiating effect of R-spondin-∆TSP on Wnt signaling (Fig.7E ). This indicates that the Wnt-signaling promoting effect of R-spondin is largely HS dependent.
Taken together, out data suggests that loss of HS inhibits Wnt signaling by impairing the binding of Wnt ligands and R-spondins to the cell surface.
Discussion
Aberrant Wnt/β-catenin pathway activity mediates cell proliferation in MM. [18] [19] [20] [21] [22] 34 In the current study, we reveal that the HS chains decorating syndecan-1 promote autocrine and 
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SUPPLEMENTAL METHODS
Flow cytometry
Confocal microscopy
The reduction in heparan sulphate expression after EXT-1 knock-out was evaluated by confocal microscopy. Cells were fixed with 4% PFA (Hatfield) for 15 minutes at room temperature. Samples were subsequently washed (TBS, 0,5% BSA) and quenched (50 mM NH4Cl and 0.5% BSA in TBS) for 15 minutes. After washing, samples were blocked for 30 minutes in TBS, 0.5% BSA with human Fc-block (Miltenyi Biotech) and stained with HSPG antibody 10E4 (1:500) (US Biological). After washing, cells were stained with directly Alexa
Fluor 488 conjugated goat anti-mouse IgM (Thermo Scientific). Then cells were mounted using MOWIOL (Calbiochem, EMD Millipore) supplemented with 2.5% triethylenediamine (Sigma-Aldrich) and 1 µg/mL Hoechst 33342 (Life Technologies,). Samples were imaged using 63x objective on a Leica TCS SP8 confocal microscope and analyzed using Leica Application Suite X (Leica Microsystems).
In vitro cell growth and apoptosis.
For the cell growth assay, cells were plated (1 x10 
Cell cycle analysis
